Corrigendum to "Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic" [Adv. Drug Delivery Rev. 179 (2021) 114000].

Samagra Jain, Abhijeet Venkataraman, Marissa E Wechsler, Nicholas A Peppas

Abstract readPublished Erratum

In one paragraph

Article in Advanced drug delivery reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed, 1 pooled it

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

Vaccines for preventing infections in adults with solid tumours.The Cochrane database of systematic reviews · 2025
Pooled it

4 · The record

Corrections and comments

Erratum for
Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic.2021

5 · Who and what money

Authors and funding

4 authors.

Samagra JainDepartment of Chemical Engineering, The University of Texas at Austin, Austin, TX, USA.

Abhijeet VenkataramanDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.

Marissa E WechslerDepartment of Biomedical Engineering and Chemical Engineering, The University of Texas at San Antonio, San Antonio, TX, USA.

Nicholas A PeppasDepartment of Chemical Engineering, The University of Texas at Austin, Austin, TX, USA; Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA; Institute for Biomaterials, Drug Delivery, and Regenerative Medicine, The University of Texas at Austin, Austin, TX, USA; Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, TX, USA; Department of Surgery and Perioperative Care, Dell Medical School, The University of Texas at Austin, Austin, TX, USA. Electronic address: peppas@che.utexas.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID36031502

DOI10.1016/j.addr.2022.114501

PMCPMC9413842

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.